Navigation Links
Biopure Announces Reverse Stock Split

CAMBRIDGE, Mass., Oct 2 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) said today that a one-for-five reverse stock split became effective at 12:01 a.m. October 2, 2007, with post-split trading expected to begin when the Nasdaq Capital Market opens today. The outstanding warrants, including those trading on the OTCBB and outstanding options have also been adjusted with the quantities reduced and the exercise prices increased by the 1-for-5 ratio.

At a special stockholder meeting on October 1, 2007, stockholders of the company authorized amending the company's certificate of incorporation to effect a reverse stock split. Pursuant to this authorization, on October 1, 2007 the board approved a one-for-five reverse split of outstanding Biopure class A common stock to take effect on October 2, 2007. The reverse split is intended to broaden Biopure's investor base and help the company gain compliance with the Nasdaq Capital Market's $1.00 minimum bid price listing requirement by increasing the share price.

The company had 77,967,938 shares of class A common stock outstanding at the end of trading on September 28, 2007. The total number of shares outstanding when the market opens on October 2, 2007 will be approximately 15,593,500. The stock is expected to trade for 20 trading days thereafter under the ticker symbol "BPURD" before reverting to "BPUR". Outstanding warrants that trade on the OTCBB will have the following new ticker symbols before reverting to the previous symbols: BPREW reverting to BPURW; BPREZ reverting to BPURZ and BPREL reverting to BPURL.

Biopure Corporation

Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. Biopure has applied in the United Kingdom for regulatory approval of a proposed orthopedic surgical anemia indication. The company is developing Hemopure for a potential indication in cardiovascular ischemia, in addition to supporting the U.S. Navy's government- funded efforts to develop a potential out-of-hospital trauma indication. Biopure's veterinary product Oxyglobin(R) [hemoglobin glutamer - 200 bovine)], or HBOC-301, the only oxygen therapeutic approved by the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs. Biopure has sold approximately 186,000 units of Oxyglobin, which have been used to treat an estimated 100,000 animals.

Statements in this release that are not strictly historical are forward-looking statements, including those statements implying that the reverse stock split may broaden Biopure's investor base or increase the per share price of Biopure Class A common stock. Actual results and their timing may differ materially from those projected in these forward-looking statements due to risks and uncertainties. These risks include, without limitation, uncertainties regarding the company's financial position, unexpected costs and expenses, delays and adverse determinations by regulatory authorities and delays in or unpredictable outcomes of clinical trials, market reaction to the reverse stock split, including the reduction in the number of shares outstanding, and the factors identified under the heading "Risk Factors" in the company's quarterly report on Form 10-Q filed on August 14, 2007, which can be accessed in the EDGAR database at the U.S. Securities and Exchange Commission's (SEC) website, The company undertakes no obligation to release publicly the results of any revisions to these forward- looking statements to reflect events or circumstances arising after the date hereof. A full discussion of the company's operations and financial condition can be found in the company's filings with the SEC.

The content of this release does not necessarily reflect the position or the policy of the U.S. Government or the Department of Defense, and no official endorsement should be inferred.


Todd Wood

Biopure Corporation

(617) 234-6576

Herb Lanzet (Investors)

H.L. Lanzet Inc.

(212) 888-4570

SOURCE Biopure Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. PM announces a new health care order for India
2. Ramdoss Announces Introduction of RCH-II
3. Britain Announces Third Transfusion Related Mad Cow Case
4. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
5. Tibet Announces the Dalai Lama’s Tour of South Americ
6. NHS announces further Cost cutting Measures
7. Indian PM Announces Of Setting Up India Study Center At Tashkent
8. PowderMed Announces Needle-Less Flu Vaccine
9. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
10. Australian Government Announces Survey To Tackle Childhood Obesity
11. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... World Patent Marketing , ... a container patent that allows for easier packing and organizing of items into one ... $90 billion," says Scott Cooper, CEO and Creative Director of World Patent Marketing and ...
(Date:12/1/2015)... ... December 01, 2015 , ... Integrated Rental Services ... Jordan Industries International, LLC (“JII”). , With support from JII, Integrated Rental is ... to hospitals, surgery centers, clinics, research labs and medical facilities across the United ...
(Date:12/1/2015)... Fla. (PRWEB) , ... December 01, 2015 , ... ... number of leadless pacemakers in the U.S. and is the only hospital in ... from the largest clinical data presentation of transcatheter pacing patients were revealed recently ...
(Date:12/1/2015)... ... December 01, 2015 , ... Growth in medical payments per workers’ compensation ... utilization of hospital and nonhospital care, according to a recent study by the Workers ... 16th Edition , found medical payments per claim with more than seven days of ...
(Date:12/1/2015)... ... ... It’s official: Tattoo taboo is a thing of the past. One in five ... one in three aged 18 to 25 is inked). As tattoos transition to mainstream ... fact, RealSelf , the world’s largest community for learning and sharing information about ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 1, 2015 ... today announced that its Chief Executive Officer, ... the Oppenheimer Annual Healthcare Conference in New ... in the conference through a webcast on ... , --> ...
(Date:12/1/2015)... Pharma Tech Outlook recently conducted a comprehensive ... Management Solution Providers - 2015 .  After careful consideration ... CIOs, VCs, analysts, and the Pharma Tech Outlook editorial ... 10 clinical data management solution providers (check out the ... 36 respectively). --> ...
(Date:12/1/2015)... , 1 de diciembre de 2015 /PRNewswire/ ... para cuchillas de precisión, develó hoy un ... identidad de marca. El nuevo logo destaca ... y la ingeniería de productos con cuchillas ... ...
Breaking Medicine Technology: